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Coronary Collateral Function Long
After Drug-Eluting Stent Implantation
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Stephan Windecker, MD, Bernhard Meier, MD, FACC, FESC, Christian Seiler, MD, FACC, FESC
Bern, Switzerland
Objectives This study was designed to compare coronary collateral function in patients after bare-metal stent (BMS) or
drug-eluting stent (DES) implantation.
Background Drug-eluting stents have an inhibitory effect on the production of cytokines, chemotactic proteins, and growth
factors, and may therefore negatively affect coronary collateral growth.
Methods A total of 120 patients with long-term stable coronary artery disease (CAD) after stent implantation were in-
cluded. Both the BMS group and the DES group comprised 60 patients matched for in-stent stenosis severity of
the vessel undergoing collateral flow index (CFI) measurement at follow-up and for the duration of follow-up. The
primary end point of the investigation was invasively determined coronary collateral function 6 months after
stent implantation. Collateral function was assessed by simultaneous aortic, coronary wedge, and central venous
pressure measurements (yielding CFI) and by intracoronary electrocardiogram during balloon occlusion.
Results There were no differences between the groups regarding age, gender, body mass index, frequency of cardiovascular
risk factors, use of cardiovascular drugs, severity of CAD, or site of coronary artery stenoses. Despite equal in-stent
stenosis severity (46  34% and 45  36%) and equal follow-up duration (6.2 10 months and 6.5  5.4 months),
CFI was diminished in the DES versus BMS group (0.154 0.097 vs. 0.224  0.142; p  0.0049), and the rate of
collaterals insufficient to prevent ischemia during occlusion (intracoronary electrocardiographic ST-segment elevation
0.1 mV) was higher with 50 of 60 patients in the DES group and 33 of 60 patients in the BMS group (p 0.001).
Conclusions Collateral function long after coronary stenting is impaired with DES (sirolimus and paclitaxel) when compared
with BMS. Considering the protective nature of collateral vessels, this could lead to more serious cardiac
events in the presence of an abrupt coronary occlusion. (J Am Coll Cardiol 2007;49:15–20) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.043t
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Drug-eluting coronary stents (DES) have been
demonstrated to decrease restenosis rates com-
pared to bare-metal stents (BMS) (1–3). The
beneficial effects of DES have been shown to
extend out to 2 years after implantation, driven
by diminished re-intervention rates (4,5).
athophysiologically, stent implantation causes endothelial
enudation; medial dissection; and exposure of the subin-
ima with subsequent platelet activation and production of
ytokines, mitogens, chemotactic proteins, and activation of
ascular smooth muscle cells (6). The anti-platelet agents
rescribed after stenting, as well as the anti-proliferative
rugs released from DES, have the purpose of mitigating
he effects of the mechanical vascular injury, thus reducing
rom the Department of Cardiology, University Hospital, Bern, Switzerland.
upported by a grant from the Swiss National Science Foundation, #3200BO-
00065/1.a
Manuscript received June 13, 2006; revised manuscript received August 17, 2006,
ccepted August 21, 2006.he incidence of stent thrombosis and in-stent restenosis.
owever, the salutary effect of DES on restenosis may be
ought at the price of toxic vascular injury, that is, delayed
ealing of the traumatized vessel wall (7), thereby height-
ning the risk of late stent thrombosis and impairing
See page 21
ndothelial-dependent vasomotion. So far, there has been
o evidence that early or mid-term stent thrombosis after
ES implantation is more frequent than in BMS-treated
atients (8,9). Conversely, endothelium-dependent coro-
ary vasomotion adjacent to DES has been demonstrated to
e impaired in practically all cases investigated so far
10,11). An additional, but thus far hypothetical, issue of
oncern has not been investigated yet: the inhibiting effect
f the drugs eluted by DES on the production of cytokines,
hemotactic proteins, and growth factors may negatively
ffect coronary collateral growth. Therefore, the goal of the
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Collateral Flow and DES January 2/9, 2007:15–20present study was to quantita-
tively compare coronary collat-
eral flow in patients 6 months
after BMS or DES implantation.
Methods
Patients. A total of 120 patients
(age 60  10 years, 101 men, 19
women) with 1- to 3-vessel long-
term stable coronary artery dis-
ease (CAD) were included in the
study. Initially, all had under-
gone percutaneous coronary in-
tervention (PCI) with stenting of
1 stenotic lesion because of
symptoms related to CAD. The
resent study focused on invasive measurements of collateral
ow index (CFI) late after either BMS or DES implanta-
ion. Sixty patients were included in the BMS group, and 60
atients were matched for the following parameters in the
ES group: 1) stenosis severity of the vessel undergoing
FI measurement at follow-up, and 2) duration of follow-
p. Patients underwent follow-up coronary angiography
ecause of recurrent chest pain. The BMS group being
atched to the prospectively and consecutively recruited
ES group was selected from our database of CFI mea-
urements, including 1,000 CFI measurements. Among
hem, 99 patients underwent coronary angiography 1 to 58
onths following stent implantation with a CFI measure-
ent and with or without the finding of in-stent restenosis.
ixty of the 99 patients with BMS could be matched to 60
ES patients according to these criteria. Additional criteria
or inclusion in the study were as follows: 1) no previous
-wave infarction, 2) no baseline electrocardiographic
ECG) ST-segment abnormalities, and 3) stable CAD. The
resent investigation was approved by our institutional
thics committee, and the patients gave informed consent to
articipate in the study.
ardiac catheterization and coronary angiography. Pa-
ients underwent left heart catheterization for diagnostic
urposes from the right femoral artery approach. Biplane
eft ventriculography was performed followed by coronary
ngiography. Central venous pressure (CVP) was measured
ia the femoral vein. Coronary artery in-stent restenosis
nd, if present, stenoses in other vascular areas were esti-
ated quantitatively as percent diameter reduction using
he guiding catheter for calibration.
oronary hemodynamic and collateral assessment. Ad-
itionally, the hemodynamic severity of (absent or present)
n-stent restenosis was measured using distal coronary
ressure-derived assessment of fractional flow reserve (FFR)
n response to intracoronary adenosine (a bolus of 12 g for
he right and 18 g for the left coronary artery).
In all patients, recruitable coronary collateral flow during
Abbreviations
and Acronyms
BMS  bare-metal stents
CAD  coronary artery
disease
CFI  collateral flow index
CVP  central venous
pressure
DES  drug-eluting stents
ECG  electrocardiographic
FFR  fractional flow
reserve
PCI  percutaneous
coronary interventionascular balloon occlusion relative to normal antegrade flow whrough the non-occluded coronary artery (CFI, no units)
as determined using coronary pressure measurements. A
.014-inch fiber-optic pressure monitoring wire (RadiWire,
adi, Upsala, Sweden) was set at zero, calibrated, advanced
hrough the guiding catheter, and positioned distal to the
ite of CFI assessment. Collateral flow index was deter-
ined by simultaneous measurements of mean aortic pres-
ure (Pao, mm Hg, via the angioplasty guiding catheter),
istal coronary occlusive pressure (Poccl, mm Hg) and CVP:
FI  (Poccl  CVP)/(Pao  CVP) (Fig. 1). Sensor-
erived CFI measurements have been previously validated
12,13).
As an additional dichotomic method for collateral assess-
ent, a unipolar intracoronary ECG was obtained in all
atients from the angioplasty guidewire (Fig. 1) aside from
surface leads. For that purpose, a cross-clamp was at-
ached close to the end of the wire and connected to ECG
ead V1 (14).
tudy protocol. Following diagnostic coronary angiogra-
hy, an interval of at least 10 min was allowed for dissipa-
ion of the effect of the contrast medium on coronary
asomotion. Before coronary hemodynamic and CFI mea-
urement, 5,000 U of heparin were given. Two puffs of oral
itroglycerin spray were applied shortly before coronary
ressure measurements. The pressure guidewire was posi-
ioned distal to the site of the angioplasty balloon occlusion
nd fractional flow reserve was obtained. During the entire
rotocol, the intracoronary ECG obtained from the pres-
ure guidewire and the surface lead ECG was recorded.
imultaneous recording of Pao via the 6-F guiding catheter,
occl, CVP, and the ECG was started before and continued
hroughout the 60-s balloon occlusion. Coronary occlusion
as performed within the stent using an appropriately sized
ngioplasty balloon. If indicated, PCI for in-stent restenosis
as performed following CFI measurement.
tatistical analysis. All patients were individually matched
etween the BMS and the DES groups according to the
uantitatively measured percent diameter narrowing of
he stenosis of interest (primary variable) and according
o the duration of follow-up after stent implantation.
etween-group comparisons (including the subgroup anal-
sis of BMS versus sirolimus- and paclitaxel-eluting stents)
f continuous demographic, angiographic, hemodynamic,
nd collateral flow data were performed by a 2-sided paired
tudent t test. The McNemar test was used for comparison
f categorical variables among the study groups. A p value
0.05 was considered statistically significant.
esults
atient characteristics and clinical data. There were no
tatistically significant differences between the 2 groups
egarding age, gender, duration of chest pain, positive
readmill exercise ECG shortly before study inclusion, body
ass index, and frequency of cardiovascular risk factors as
ell as the use of cardiovascular drugs (Table 1).
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January 2/9, 2007:15–20 Collateral Flow and DESoronary angiographic data. The coronary arteries initially
ndergoing PCI with stenting were similarly distributed
mong the groups (Table 2). There was no difference between
he groups in the number of coronary arteries diseased. Among
atients with1-vessel CAD, coronary arteries other than the
arget vessel had hemodynamically irrelevant stenotic lesions
i.e., 50% diameter stenosis). The vascular location where
FI measurement and/or PCI was performed was similar
etween the groups. Stenosis severity before stent implantation
id not differ significantly between the groups. In the DES
roup, 37 patients had received sirolimus-eluting stents, and 23
atients had been treated with paclitaxel-eluting stents.
ollow-up duration since stent implantation (median 4.15
onths in the BMS group and 4.95 months in the DES
roup) and percent diameter stenosis of the target vessel at
ollow-up was equal between the groups (Table 2). The
requency of PCI as compared to balloon occlusion without
CI at follow-up was very similar between the groups (Table
). There was no difference in the balloon inflation pressure,
Figure 1 Collateral Function Determination
Determination of collateral function in a patient with a bare-metal stent (BMS) (lef
cardiogram (ECG) lead recording (apart from surface lead recordings) is shown in t
both patients show signs of myocardial ischemia, although those in the BMS grou
calculated by dividing mean distal coronary occlusive pressure (Poccl, mm Hg; scale
Hg) by mean aortic pressure (Pao, mm Hg; scale 0 to 150 mm Hg) minus CVP.hereas in patients undergoing balloon occlusion without PCI lhe difference always amounted to 1 to 2 atm. Angioplasty
alloon size was similar between the groups (Table 2).
emodynamic and collateral circulation data. Heart rate,
rterial blood pressure, left ventricular ejection fraction, left
entricular end-diastolic pressure, central venous pressure im-
ediately before vascular occlusion, and FFR were similar
etween the groups (Table 3). The occurrence of angina
ectoris during the 1-min coronary occlusion did not differ
etween the groups. However, ST-segment elevation 1 mm
n intracoronary ECG (i.e., insufficient collateral flow) was
een significantly less often in the BMS group than in the DES
roup. Collateral flow index was significantly higher in the
MS group than in the DES group (Table 3, Fig. 2). This
ifference was less pronounced among patients with a
irolimus-eluting than with a paclitaxel-eluting stent.
iscussion
he novel result of this study is that coronary collateral
unction 6 months after implantation of a DES is 30% to 40%
a patient with a drug-eluting stent (DES) (right). The intracoronary (i.c.) electro-
er part of the figure. During coronary balloon occlusion, the i.c. ECG leads of
uch less pronounced than those in the DES group. Collateral flow index (CFI) is
200 mm Hg) minus central venous pressure (CVP, mm Hg; scale 0 to 50 mmt) and
he upp
p are m
0 toower than that obtained equally long after BMS implantation.
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Collateral Flow and DES January 2/9, 2007:15–20onsidering the salvaging effect of well-grown collaterals, a
otential clinical impact of this finding is that in the presence
f stent thrombosis myocardial infarct size and, thus, mortality
ay be larger in DES- than in BMS-treated patients.
eterminants of coronary collateral function aside from
he drugs eluted by DES. The overlap of CFI values
mong the study groups (Fig. 2) indicates that the associa-
atient Characteristics and Clinical Data
Table 1 Patient Characteristics and Clinical Data
BMS DES
p
Value
Number of patients 60 60
Age (yrs) 59 10 61 13 0.21
Male gender 51 50 1.0
Duration of chest pain (months) 1.2 2.2 1.4 2.5 0.63
Positive treadmill exercise ECG 26 28 0.82
Body mass index (kg/m2) 28 3 30 21 0.21
Smoking 20 19 0.85
Hypercholesterolemia 40 44 0.70
Hypertension 34 34 0.99
Obesity 21 26 0.23
Family history of CAD 16 17 0.45
Diabetes mellitus 8 4 0.24
Acetylsalicylic acid 56 56 1.0
Beta-blockers 45 52 0.17
Calcium antagonists 12 11 0.92
Nitrates 16 14 0.77
Angiotensin-converting enzyme inhibitor 19 21 0.88
Statin 45 46 0.92
Diuretics 9 11 0.65
alues expressed as n unless otherwise specified.
BMS  bare-metal stents; CAD  coronary artery disease; DES  drug-eluting stents; ECG 
lectrocardiogram.
Coronary Angiographic Data
Table 2 Coronary Angiographic Data
Vessel undergoing PCI (n)
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Number of diseased vessels (n)
1
2
3
Site of stenosis undergoing PCI (n)
Proximal segment
Mid segment
Distal segment
% diameter stenosis before stent implantation
DES: sirolimus/paclitaxel (n)
Follow-up since stent implantation (months)*
% diameter stenosis at follow-up
PCI/balloon occlusion without PCI at follow-up (n)
Balloon inflation pressure in PCI cases (atm)
Angioplasty balloon size (mm)*That is, at the time of collateral flow index measurement.
PCI  percutaneous coronary intervention; other abbreviations as in Tableion between DES and impaired collateral function is not
ntirely clear cut, that is, other, perhaps unevenly distributed
actors could be responsible for the CFI difference. Numer-
us clinical factors have been reported to influence the
uman coronary collateral circulation: age, gender, hyper-
holesterolemia, arterial hypertension, presence of diabetes
ellitus, statins, and other cardiovascular drugs (15). How-
ver, very few pathogenetic factors have been consistently
escribed to be related to well-developed coronary collater-
ls (i.e., the duration of myocardial ischemic symptoms and
he severity of arterial stenotic lesions) (16,17). In the
resent study, none of the putative and unconfirmed factors
iffered between the groups (Tables 1 and 2). The indis-
utable co-determinants of collaterals were accounted for by
atching the cases of both groups one by one for stenosis
everity at the time of CFI measurement and for the
uration following BMS or DES implantation. Considering
hat individuals without coronary stenoses have variably
reformed anastomoses between vascular territories (18),
here must be other factors influencing the collateral circu-
ation, such as genetic predisposition for well or poorly
rown collateral arteries. We did not correct for these
actors in the present investigation, and by chance, they may
ave been unevenly distributed among the groups. How-
ver, the likelihood that CFI in patients after DES was
orse than after BMS implantation for reasons entirely
ifferent from DES can be regarded as very low.
ES as determinants of coronary collateral function. Is
here evidence from experimental studies to support and
echanistically explain the relevance of DES as determi-
ants of coronary collateral function? There is, but exclu-
BMS
n  60)
DES
(n  60) p Value
0.43
32 26
10 11
18 23
0.34
15 10
31 33
14 17
0.90
44 45
14 13
2 2
6 22 89 30 0.63
— 37/23
.2 10.0 6.5 5.4 0.82
6 34 45 36 0.77
39/21 37/23 0.91
5 6 15 8 0.73
5 0.45 3.10 0.52 0.80(
8
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January 2/9, 2007:15–20 Collateral Flow and DESively for sirolimus/rapamycin as the drug eluted by the
tent. Guba et al. (19) documented that rapamycin inhibited
etastatic tumor growth in in vivo mouse models when
ompared to conventional immunosuppression with cyclo-
porine. The finding appeared to be related to rapamycin
ossessing anti-angiogenic properties linked both to a de-
rease in the production of vascular endothelial growth
actor and to an inhibited response of vascular endothelial
ells to stimulation by vascular endothelial growth factor.
ecently, Fukuda et al. (20) found that peripheral blood
ononuclear cells from healthy human volunteers were
nhibited by sirolimus to outgrow to smooth muscle-like
ells (the principle component of neointimal hyperplasia)
nd to endothelial cell-like cells. Thus, although the clinical
fficacy of sirolimus-eluting stents against restenosis is very
ikely achieved by their inhibitory effect on smooth muscle
rogenitors, re-endothelialization following vascular injury
Hemodynamic and Collateral Circulation Data
Table 3 Hemodynamic and Collateral Circul
Heart rate (beats/min)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
LV ejection fraction (%)
LV end-diastolic pressure (mm Hg)
Central venous pressure (mm Hg)
FFR in the stented vessel (no units)
Coronary collateral circulation (n)
Angina pectoris during balloon occlusion
i.c. ECG ST-segment elevation 1 mm during occlusion
Collateral flow index (CFI, no unit)
CFI in patients with sirolimus stents
CFI in patients with paclitaxel stents
CFI collateral flow index; ECG electrocardiographic; FFR fraction
coronary intervention; other abbreviations as in Table 1.
Figure 2 Individual Collateral Flow Index Data
Intergroup difference in individual collateral flow index values (CFI) ().
Red triangles  mean values; error bars  1 SD.say promote stent thrombosis (21), and the decrease in
oth these cellular elements may impede collateral growth.
n a human organ culture model (renal artery segments),
apamycin has even been documented to have an effect on
ranscriptional programs governing neointima formation
22). In the study by Nührenberg et al. (22), many of the
enes differentially regulated in response to rapamycin were
elated to recruitment of blood cells and inflammatory
eactions of the vessel wall. Thus, to account for genetic
ariability in the present study would have likely detected a
rug effect and not an accidental maldistribution in the
enetic background between the groups.
nti-arteriogenic effect of DES and its potential clinical
mpact. Is there, aside from the present study’s findings,
vidence from clinical investigations consistent with the
bove described pathophysiologic mechanisms elicited by
ES? Togni et al. (10) and Hofma et al. (11) respectively
escribed flow-induced (physical exercise) acetylcholine-
nduced endothelial dysfunction in 3 of 16 patients follow-
ng BMS implantation but in the vast majority of patients
18 of 21) after DES implantation. Considering that endo-
helial dysfunction can be regarded as the earliest stage of
therosclerosis, and its presence foretells adverse cardiovas-
ular events (23), an unfavorable clinical impact related to
ES can be imagined. Such an interpretation is propagated
y data from the literature indicating that a decrease in
irculating endothelial progenitor cells is associated with an
ncreased frequency of cardiovascular disease (24). However,
he adverse effect of DES on endothelial structural repair
nd function has so far been shown exclusively for sirolimus-
luting stents. In this regard, the present study contributes
wo new findings aside from the principal one of the
nti-arteriogenic effect of DES: first, both sirolimus and
aclitaxel elicit a negative effect on collateral function, and
econd, the effect of sirolimus appears to be less pronounced
han that of paclitaxel (Table 3). Clinically, the fact of a
Data
BMS
(n  60)
DES
(n  60) p Value
66 13 69 11 0.11
130 23 125 21 0.50
71 12 69 10 0.72
65 11 64 10 0.72
13 7 12 6 0.30
6 2 5 3 0.44
0.828 0.184 0.838 0.177 0.88
38 39 0.51
33 50 0.001
0.224 0.142 0.154 0.097 0.0049
0.224 0.142 0.169 0.109 0.05
0.224 0.142 0.131 0.072 0.007
reserve; i.c. intracoronary; LV left ventricular; PCI percutaneousationignificantly higher CFI in the BMS than the DES group
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Collateral Flow and DES January 2/9, 2007:15–20ranslates into a reduced frequency of about 1 of 2 patients
ith ECG signs of ischemia during coronary occlusion versus
of 6 in the DES group. Having said that, it becomes also
vident that the effect of different stents on collateral function
as assessed by two independent methods that have been
xtensively validated (13).
Our study’s new finding of a DES-induced anti-
rteriogenic effect creates a further clinical risk aside from
hat of more frequent cardiovascular events due to endothe-
ial dysfunction and deficit of endothelial progenitor cells. In
he event of stent thrombosis, impaired collateral function
n patients with DES could render the thrombosis more
angerous (i.e., could worsen the consequences of abrupt
oronary occlusion by increasing mortality). In support of
his notion, 6-month mortality after BMS stent thrombosis
as been found to amount to 11% (10 of 95 stent throm-
oses in 6,058 patients) (8) to 21% (11 of 53 stent
hromboses in 6,219 patients) (25), whereas that after
ES-stent thrombosis has been 29% (2 of 7 stent throm-
oses in 2,006 patients) (9) to 45% (13 of 29 stent
hromboses in 2,229 patients) (26).
tudy limitations. Aside from the previously cited limita-
ions, the present investigation is a cross-sectional rather
han a longitudinal observation of collateral function in
MS- and DES-treated patients. The ideal study design
ould have a randomized group allocation with baseline and
ollow-up CFI measurement allowing intra- and inter-
roup comparisons. Because nowadays the vast majority of
ur patients routinely receive DES, such a design would be
thically questionable.
The quality of matching was not absolute, that is, not 1:1
or both percentage points of diameter stenosis and days of
ollow-up. However, the quality of matching was so high
hat, statistically, an influence of stenosis severity and/or
ollow-up duration on the study’s main outcome can be
uled out.
eprint requests and correspondence: Dr. Christian Seiler,
rofessor and Co-Chairman of Cardiology, University Hospital,
H-3010 Bern, Switzerland. E-mail: christian.seiler@insel.ch.
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